Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Neoplasms 2COVID-19 2

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

Terminated
2,206 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡